Clinical and economic analysis of the 1st and 2nd target lines

• Main Authors: I. N. D’yakov, S. K. Zyryanov
• Format: Article
• Language: Russian
• Published: ABV-press 2016-12-01
• Series: Onkourologiâ
• Subjects: renal carcinoma; advanced renal cell carcinoma; target therapy; tyrosine kinase inhibitor; pazopanib; sunitinib; aksitinib; bevacizumab; interferon alfa; everolimus
• Online Access: https://oncourology.abvpress.ru/oncur/article/view/640

Malignant tumors represent a serious problem for healthcare system. At this time, an annual incidence of cancer rate has increased both in Russia and around the world. Renal cancer has 2 % in the structure of oncological incidence. However, in many countries we can see significant increase in oncological incidence and associated mortality. Renal cell carcinoma (RCC) takes the 2nd place after prostate tumors by the growth rate of these parameters: each year more than 200 thousand people become ill with RCC all over the world. Cytokine therapy with interleukin-2 and/or interferon alpha was the standard treatment of the advanced renal cell carcinoma until 2005. However, method of the target therapy became widespread in the last decade. This method is based on the directional drug effect on tumor cells which increases efficiency and safety of the therapy. The use of targeted therapy drugs led to a significant increase in survival rate in RCC patients. In the present review we observe clinical efficacy of the drugs used in the 1st and 2nd line of RCC treatment as well as pharmacoeconomic aspects of their application.